 |
|
 |
|
|
|
|
|
Home : Advanced Search : Course view :
|
 
| Course: |
Current Updates in the Treatment of Breast Cancer |
| Target Audience: |
This activity has been designed to meet the educational needs of oncologists, oncology fellows and oncology nurses involved in the care of patients with breast cancer.
Program Overview:
The American Cancer Society estimates that there will be 271,530 cancer-related deaths among women during 2008. Of the various types of cancer, breast cancer is the second most fatal and accounts for 15% or 40,480 deaths among women and an additional 450 deaths among men. Further, it is estimated that nearly 155,000 women in the US are currently living with advanced breast cancer and this number is projected to increase to nearly 162,000 by the year 2011.
Recent advances and regimens in advanced breast cancer therapy are being actively investigated for their ability to improve patients' clinical outcomes. These include the development of novel targeted therapies and the use of combination regimens that incorporate novel cytotoxic or biologic agents. These advances are likely to be of particular interest to practicing oncologists in the management and treatment of patients with metastatic breast cancer and present important learning opportunities for these clinicians. |
| Sponsor: |
| Jointly sponsored by Postgraduate Institute for Medicine and Medical Dialogues Group.
|
| Accreditation: |
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Medical Dialogues Group. PIM is accredited by the ACCME to provide continuing medical education for physicians.
www.pimed.com
|
| Credit Designation: |
| Postgraduate Institute for Medicine designates this educational activity for a maximum of .75 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| Faculty Listing: |
Stefan Gluck, MD, PhD, FRCPC
Sylvester Professor
Department of Medicine
Sylvester Comprehensive Cancer Center
|
| Subjects: |
- Current Updates in the Treatment of Breast Cancer
|
| Objectives: |
- Describe recent data regarding the prevalence of Vitamin D deficiency in those with breast cancer.
- Cite recent clinical data regarding the predictors of clinical response in breast cancer treatment trials.
- Review some important recently presented clinical trial data regarding cytotoxic and targeted therapies and their application to clinical practice.
- Describe the adjuvant and neoadjuvant regimens, including newer agents and combinations being used in clinical treatment trials.
|
| Financial Disclosure: |
Stefan Gluck, MD, PhD, FRCPC:
Consulting Fee – Eli Lilly, Genentech, Genomic Health, GSK, Novartis, Pfizer, Roche, Sanofi-Aventis
Non-CME Services – Eli Lilly, Genentech, Genomic Health, GSK, Novartis, Pfizer, Roche, Sanofi-Aventis
Contracted Research – Abraxis, Eli Lilly, Genentech, Genomic Health, GSK, Novartis, Pfizer, Roche, Sanofi-Aventis
The following Medical Dialogues Group planners and managers, Rick Rodes and Susan Ruffalo, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity.
The following PIM planners and managers, Linda Graham, RN, BSN, BA, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, Julia Kirkwood, RN, BSN and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Disclaimer
The materials published on CME University reflect the views of the reviewers or authors of the courses, not those of Postgraduate Institute for Medicine, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
- You are not currently logged in.
- To view content articles and complete the post-test for this course, please login or register now
|
|
|
|
|
